Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Targeting TAMs in follicular lymphoma

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the impact of tumor-associated macrophages (TAMs) in follicular lymphoma (FL), commenting on the potential of targeting these cells to improve patient outcomes. Multiple studies have demonstrated the association between macrophage gene expression profiles and outcomes in patients with FL treated with frontline chemoimmunotherapy. Dr Strati explains that following the results of the RELEVANCE study (NCT01650701) proving the non-inferiority of rituximab-lenalidomide (R2) compared to frontline chemoimmunotherapy, an increasing number of patients are being treated with R2 in the frontline setting. In a recent study, it was also shown that CD47 and SIRPα were key players mediating the crosstalk between lymphoma cells and macrophages, which has led to several early phase studies investigating the safety and efficacy of SIRPα inhibitors (CC-95251) as well as anti-CD47 antibodies (ALX148) in relapsed/refractory (R/R) patients or in previously untreated patients in combination with R2 respectively. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.